Clostridium difficile: improving the prevention paradigm in healthcare settings (Q35222472)

7 August 2017

Clostridium difficile: improving the prevention paradigm in healthcare settings (English)

1 reference

7 August 2017

Clostridium difficile

0 references

author

Ellie J. C. Goldstein

series ordinal

3

object named as

Ellie J C Goldstein

1 reference

7 August 2017

Angela Vassallo

1

1 reference

PubMed ID

25109301

7 August 2017

Mai-Chi N Tran

series ordinal

2

1 reference

7 August 2017

1 September 2014

1 reference

Expert Review of Anti-infective Therapy

7 August 2017

1 reference

7 August 2017

12

1 reference

7 August 2017

9

1 reference

7 August 2017

1087-1102

1 reference

INTESTINAL FLORA IN NEW-BORN INFANTS

7 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Antibiotic-Associated Pseudomembranous Colitis Due to Toxin-Producing Clostridia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Overlapping roles for toxins in Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Outcomes and costs associated with robotic colectomy in the minimally invasive era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Outpatient healthcare settings and transmission of Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

An epidemic, toxin gene-variant strain of Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Measures to control and prevent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Clostridium difficile PCR ribotype 078 toxinotype V found in diarrhoeal pigs identical to isolates from affected humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Clostridium difficile in ground meat, France

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Clostridium difficile in retail meat products, USA, 2007

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Risk factors for Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Clostridium difficile carriage in healthy infants in the community: a potential reservoir for pathogenic strains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Type-specific risk factors and outcome in an outbreak with 2 different Clostridium difficile types simultaneously in 1 hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Successful combat of an outbreak due to Clostridium difficile PCR ribotype 027 and recognition of specific risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Risk factors for development of Clostridium difficile infection due to BI/NAP1/027 strain: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Possible association between obesity and Clostridium difficile infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Pathways in microbe-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Obesity as a risk factor for Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Incidence of Clostridium difficile infection in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Inflammatory bowel diseases phenotype, C. difficile and NOD2 genotype are associated with shifts in human ileum associated microbial composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

21 January 2018

Colonization resistance

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

The microecology of Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Monitoring of stool microbiota in subjects with diarrhea indicates distortions in composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Effect of antibiotic therapy on human fecal microbiota and the relation to the development of Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Clinical practice. Antibiotic-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Community-associated Clostridium difficile infection and antibiotics: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Colonization for the prevention of Clostridium difficile disease in hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Quantitative study of antibiotic-induced susceptibility to Clostridium difficile enterocecitis in hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Fluoroquinolone use and Clostridium difficile-associated diarrhea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Tigecycline: a new glycylcycline for treatment of serious infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993-2007 in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Antibiotic activity against genotypically distinct and indistinguishable Clostridium difficile isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

The in-vitro activity of doxycycline and minocycline against anaerobic bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Epidemiology of community-acquired Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Does doxycycline protect against development of Clostridium difficile infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Antimicrobial stewardship and Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Approaching zero: temporal effects of a restrictive antibiotic policy on hospital-acquired Clostridium difficile, extended-spectrum β-lactamase-producing coliforms and meticillin-resistant Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

An evaluation of the impact of antibiotic stewardship on reducing the use of high-risk antibiotics and its effect on the incidence of Clostridium difficile infection in hospital settings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Favorable Impact of a Multidisciplinary Antibiotic Management Program Conducted During 7 Years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Successful use of feedback to improve antibiotic prescribing and reduce Clostridium difficile infection: a controlled interrupted time series

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Preventing clostridium difficile infection in the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Comparative role of antibiotic and proton pump inhibitor in experimental Clostridium difficile infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Hydrolytic enzyme production by Clostridium difficile and its relationship to toxin production and virulence in the hamster model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Occurrence and significance of gastric colonization during acid-inhibitory therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Does confounding explain the association between PPIs and Clostridium difficile-related diarrhea?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Risk of Clostridium difficile infection with acid-suppressive therapy; pitfalls in accurate estimation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Incidence of Clostridium difficile infections in patients receiving antimicrobial and acid-suppression therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

21 January 2018

The risks of PPI therapy

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Proton pump inhibitors and risk for recurrent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Probiotics in human infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

New methods for selecting and evaluating probiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections: enhanced and sustained decrease in the incidence and severity of infection at a community hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Controversies in the management of the critically ill: the role of probiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Is primary prevention of Clostridium difficile infection possible with specific probiotics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Narrative review: the new epidemic of Clostridium difficile-associated enteric disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Pleiotropic effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Statin use and the risk of Clostridium difficile in academic medical centres

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Do statins protect against the development of Clostridium difficile-associated diarrhoea?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

The effects of statins on the clinical outcomes of Clostridium difficile infection in hospitalised patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Reduction in mortality associated with statin therapy in patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Clinically important interaction between statin drugs and Clostridium difficile toxin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Hospital epidemiology and infection control in acute-care settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Contamination of healthcare workers' hands with Clostridium difficile spores after caring for patients with C. difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

What is on that keyboard? Detecting hidden environmental reservoirs of Clostridium difficile during an outbreak associated with North American pulsed-field gel electrophoresis type 1 strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

An evaluation of environmental decontamination with hydrogen peroxide vapor for reducing the risk of patient acquisition of multidrug-resistant organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Evaluation of a pulsed-xenon ultraviolet room disinfection device for impact on hospital operations and microbial reduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

The effect of portable pulsed xenon ultraviolet light after terminal cleaning on hospital-associated Clostridium difficile infection in a community hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Implementation of innovative pulsed xenon ultraviolet (PX-UV) environmental cleaning in an acute care hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Effect of antibiotic stewardship programmes on Clostridium difficile incidence: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Medication risk factors associated with healthcare-associated Clostridium difficile infection: a multilevel model case-control study among 64 US academic medical centres

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Antibiotic use and other risk factors at hospital level for outbreaks with Clostridium difficile PCR ribotype 027.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.942284

10.1586/14787210.2014.942284

21 January 2018

Identifiers

DOI

1 reference

7 August 2017

1 reference

PubMed ID

25109301